News And Media

  • 2018

     

    05/06/2018

    Report on the General Meeting of June 4, 2018
     

    15/05/2018

    Convening of another Combined General Meeting on June 4, 2018
     

    30/04/2018

    STENTYS completes the acquisition of MINVASYS
     

    12/04/2018

    Financial Information for the First Quarter of 2018
     

    03/04/2018

    2017 Annual Results
     

    14/03/2018

    STENTYS announces the success of its €11.8 million rights issue to finance the acquisition of MINVASYS
     

    21/02/2018

    STENTYS launches a €11.8 million rights issue to finance the acquisition of MINVASYS
     

    30/01/2018

    STENTYS announces plans to acquire MINVASYS
     

    08/01/2018

    2017 Annual Revenues
     

    03/01/2018

    2018 Financial Calendar
     
  • 2017

     

    08/11/2017

    STENTYS announces the pre-commercialization of SERPENTIS, its new latest-generation of active stent
     

    12/10/2017

    Revenues for the Third Quarter of 2017: Continued Growth for the Xposition S Stent
     

    02/10/2017

    2017 half-year results
     

    27/07/2017

    STENTYS Completes Enrollment of the TRUNC Study
     

    03/04/2017

    STENTYS is strengthening its Board by co-opting two new independent members
     

    03/04/2017

    STENTYS is strengthening its Board by co-opting two new independent members
     

    21/03/2017

    2016 Annual Results
     
  • 2016

     

    12/10/2016

    STENTYS Reports 26% Year-over-Year Growth in Nine-Month 2016 Revenues
     

    12/10/2016

    STENTYS Reports 26% Year-over-Year Growth in Nine-Month 2016 Revenues
     

    15/09/2016

    2016 First-Half Results
     

    12/07/2016

    41% Increase in Revenues in the Second Quarter of 2016
     

    06/07/2016

    STENTYS: Appointment of Cardiovascular Device Veteran as New CEO
     

    08/06/2016

    STENTYS Announces CE Marking of its longest Xposition stent
     

    12/05/2016

    Convening of another Annual General Meeting on June 16, 2016
     

    13/04/2016

    STENTYS Reports 38% Increase in Revenues in First Quarter 2016
     

    21/03/2016

    STENTYS Announces the CE Marking of the Self-Apposing Stent for Left Main Coronary Artery Disease
     

    16/03/2016

    2015 Annual Results
     

    04/03/2016

    Succes of a 12.6m rights issue
     

    29/02/2016

    Results of Self-Apposing Sirolimus-Eluting Stent Trial Published in EuroIntervention
     

    08/02/2016

    Launch of the Commercialization of the first Self-Expanding Drug-Eluting stent for the Below-The-Knee Indication
     

    28/01/2016

    STENTYS: First Intervention with the Self-Apposing Drug-Eluting Stent for Lower Limbs broadcasted live at LINC international congress
     

    13/01/2016

    STENTYS Reports 81% Year-over-Year Growth in Fourth-Quarter 2015 Revenues
     
  • 2015

     

    22/12/2015

    2016 Financial Agenda
     

    09/12/2015

    STENTYS: Enrollment Completion of MiStent Randomized Trial against Xience
     

    12/10/2015

    STENTYS Sirolimus-Eluting Stent Confirms Best-in-Class Performance at 3 Years
     

    17/09/2015

    First Half 2015 Financial Results
     

    08/07/2015

    STENTYS Reports 40% Increase in Revenues in Second Quarter of 2015
     

    16/06/2015

    Report on the Combined Shareholders’ Meeting of June 15, 2015
     

    19/05/2015

    First Clinical Experience with Xposition shows 100% implantation success, Confirms Ease of Use
     

    05/05/2015

    STENTYS: convening of another combined Shareholders’ Meeting on June 15, 2015
     

    28/04/2015

    STENTYS’ Next-Generation of Self-Apposing Stent System Receives CE Marking Ahead of Plan
     

    16/04/2015

    STENTYS Reports First Quarter 2015 Revenues Rose 28
     

    31/03/2015

    2014 Annual Results
     

    23/02/2015

    Results of largest STENTYS Stent Trial in Myocardial Infarction Published in EuroIntervention
     

    12/02/2015

    New Self-Apposing Stent Study in Left Main Coronary Artery
     

    12/02/2015

    STENTYS Announces the Publication of New Self-Apposing Stent Study in Left Main Coronary Artery
     

    28/01/2015

    STENTYS Expands Benefits of First Drug-Eluting, Self-Expanding Stent to Lower Limb Artery Disease
     

    22/01/2015

    STENTYS 2014 Annual Revenues up 13% to €3.9 Million
     
  • 2014

     

    03/11/2014

    STENTYS enrichit son offre de produits à toutes les indications coronaires par un accord exclusif avec Micell pour distribuer son stent actif innovant
     

    30/10/2014

    Communiqué de mise à disposition du Document de référence 2013
     

    27/10/2014

    STENTYS’ Sirolimus-Eluting Stent Receives CE Marking
     

    23/10/2014

    STENTYS Revenues for the First 9 Months of 2014 up 16.9 percent
     

    20/10/2014

    STENTYS Wins Large Regional Tender in Middle East
     

    25/09/2014

    STENTYS Adds Branch Office in Dubai
     

    22/09/2014

    First Half 2014 Financial Results
     

    16/09/2014

    STENTYS Stent continues to show low mortality two years after treatment of a heart attack
     

    03/09/2014

    STENTYS Reaches 10,000 Self-Apposing Stent implantations
     

    25/08/2014

    STENTYS to Report First-Half Results on September 22, 2014
     

    31/07/2014

    STENTYS Reallocates Resources to focus on its Advanced Drug-Eluting Stent Program
     

    31/07/2014

    STENTYS Reallocates Resources to focus on its Advanced Drug-Eluting Stent Program
     

    24/07/2014

    STENTYS First Half 2014 Revenues Rise 18pc
     

    09/07/2014

    STENTYS Expands Marketing of the Self-Apposing Stent in South America
     

    12/06/2014

    STENTYS Completes the Acquisition of Cappella Peel Away Inc.
     

    04/06/2014

    STENTYS to Acquire Stent Delivery Technology for Its Next-Generation of Self-Apposing Stents
     

    27/05/2014

    STENTYS Self-Apposing Stent Featured Prominently at 2014 EuroPCR Conference
     

    20/05/2014

    STENTYS Sirolimus-Eluting Stent Demonstrates Best in Class Efficacy for Heart Attack Patients
     

    14/05/2014

    STENTYS Secures a Standby Equity Facility
     

    07/05/2014

    STENTYS: Journal of the American College of Cardiology Publication Shows Malapposition Influences Death from Early Stent Thrombosis
     

    29/04/2014

    STENTYS’ Self-Apposing Stent Featured in New Article Published by the Journal of the American College of Cardiology
     

    24/04/2014

    STENTYS First Quarter Revenues Up 18% from 2013
     

    10/04/2014

    STENTYS appoints Medical Device Executive to its Board of Directors
     

    31/03/2014

    STENTYS shares eligible for new PEA-PME savings plan
     

    13/03/2014

    2013 full-year results
     

    23/01/2014

    2013 Annual Revenues Up 34% From 2012
     

    08/01/2014

    STENTYS Expands Marketing of its Stents in Asia
     

    06/01/2014

    Financial agenda 2014
     
  • 2013

     

    30/10/2013

    STENTYS Self-Apposing Stent performs well in new coronary indications
     

    29/10/2013

    STENTYS Sirolimus-eluting stent demonstrates faster arterial healing than conventional drug-eluting stent
     

    24/10/2013

    STENTYS Revenues for the First 9 Months of 2013 Up 32% Over Prior Year
     

    21/10/2013

    STENTYS to Present first results of Sirolimuseluting Self-Apposing® Stent at TCT Conference
     

    29/08/2013

    Improved Bottom Line on the Company’s Historical Activity over the H1 2013
     

    25/07/2013

    Revenues for the First Half of 2013 Up 43% Over Prior Year
     

    10/07/2013

    STENTYS Self-Apposing Stent Approved in Europe for Additional Coronary Indications
     

    22/05/2013

    Further Data on STENTYS Self-Apposing Stent Reinforces Strength of Clinical Results
     

    20/05/2013

    STENTYS Enrolls First Heart Attack Patient in Pivotal U.S. Clinical Trial
     

    02/05/2013

    PRESS RELEASE
     

    25/04/2013

    Revenues for the First Quarter of 2013 Up 47% Over Prior Year
     

    28/03/2013

    2012 annual results
     

    09/03/2013

    STENTYS Self-Apposing® Stent Demonstrates Lowest Mortality Rate Among Large Heart Attack Trials
     

    26/02/2013

    STENTYS to Present Final Results From 1,000 Heart Attack Patient Study at ACC.13
     

    23/01/2013

    2012 annual revenues up 77% over prior year
     

    10/01/2013

    Financial agenda for 2013
     

    03/01/2013

    STENTYS clinical study demonstrating superiority of SelfApposing® stents over conventional stents published in American College of Cardiology journal
     
  • 2012

     

    09/11/2012

    Revenues for the 3rd quarter 2011
     

    22/10/2012

    STENTYS Self-Apposing® Stent continues to demonstrate low mortality at one year in APPOSITION III trial
     

    22/10/2012

    STENTYS Receives FDA Approval to Initiate First U.S. Clinical Trial With Self-Apposing® Stent
     

    15/10/2012

    STENTYS to Present One-Year Interim Results From APPOSITION III Study at TCT Conference
     

    26/09/2012

    STENTYS Launches New Stent-Delivery System to Facilitate Implantation in More Complex Vessel Anatomies
     

    30/08/2012

    2012 Half-Year results
     

    25/07/2012

    Revenues for the first half of 2012 +92%
     

    14/06/2012

    STENTYS starts clinical trial to broaden portfolio with new drug-eluting stent
     

    16/05/2012

    STENTYS Self-Apposing® Stent shows very low mortality at one month in 1,000 high risk heart attack patients
     

    14/05/2012

    STENTYS expands its product offerings for treating heart attacks
     

    02/05/2012

    Revenues for the first quarter of 2012
     

    26/03/2012

    STENTYS Self-Apposing technology supported by breaking new scientific evidence
     

    07/03/2012

    2011 Financial Results
     

    08/02/2012

    Increased reimbursement of Self-Expanding drug-eluting stents in Germany now for all indications
     

    01/02/2012

    STENTYS concludes clinical trial ahead of plan
     

    26/01/2012

    STENTYS raises €8.3m in capital
     

    25/01/2012

    Private placement
     

    16/01/2012

    Full-Year Sales for 2011
     
  • 2011

     

    13/12/2011

    Financial agenda for 2012
     

    08/11/2011

    Outstanding interim results of STENTYS international clinical study of 600 heart attack patients
     

    12/10/2011

    STENTYS Self-Apposing Stents in “perfect apposition to vessels” after treating patients with heart attacks
     

    21/09/2011

    STENTYS compeltes enrollement of APPOSITION III study for its Self-Apposing Stent to Treat Heart Attacks
     

    15/09/2011

    Over 1000 patients have benefited from STENTYS Self-Apposing technology
     

    31/08/2011

    STENTYS reports six-month 2011 Financial results
     

    26/07/2011

    Revenues for the 1 half of 2011
     

    20/06/2011

    Prof. Gilles Montalescot joins STENTYS Scientific Advisory Board
     

    08/06/2011

    STENTYS recruits Country Managers for France and Italy
     

    18/05/2011

    STENTYS joins Stent for Life Initiative to expand optimal heart attack treatment across Europe
     

    16/05/2011

    Stenting in STEMI: Does Size Matter?
     

    11/05/2011

    Significant revenue increase in the 1st quarter of 2011
     

    02/05/2011

    STENTYS enrolls first 250 patients, half of Apposition III study of its Self-Apposing Stent for treatment of Heart Attacks
     

    24/03/2011

    2011 FY 2010 financial results
     

    17/03/2011

    STENTYS expands operations into four additional European countries
     

    23/02/2011

    Increased reimbursement of STENTYS drug-eluting stent in Germany
     

    08/02/2011

    Full year 2010 revenues
     

    24/01/2011

    Financial events for 2011
     
  • 2010

     

    09/12/2010

    Launch of APPOSITION III - 50 patients already enrolled
     

    23/11/2010

    STENTYS appoints Michel Darnaud to its Board of Directors
     

    19/11/2010

    Definitive amount of capital increase and Communication regarding the details of stabilisation operations
     

    15/11/2010

    Steady Growth in Q3 2010
     

    22/10/2010

    Successful IPO of STENTYS on NYSE Euronext Paris
     

    12/10/2010

    STENTYS launches its initial public offering on NYS E Euronext Paris
     

    09/09/2010

    First step towards Initial Public Offering on the Paris NYSE Euronext market
     

Page ID 1241   |   Last edited 2017/10/16